Market Cap | 262.67M | P/E | - | EPS this Y | -4.00% | Ern Qtrly Grth | - |
Income | -60.39M | Forward P/E | -3.37 | EPS next Y | 3.20% | 50D Avg Chg | -4.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -14.00% |
Dividend | N/A | Price/Book | 1.64 | EPS next 5Y | - | 52W High Chg | -53.00% |
Recommedations | 1.90 | Quick Ratio | 9.58 | Shares Outstanding | 30.87M | 52W Low Chg | 49.00% |
Insider Own | 17.56% | ROA | -26.25% | Shares Float | 8.95M | Beta | - |
Inst Own | 69.78% | ROE | -41.41% | Shares Shorted/Prior | 1.03M/484.04K | Price | 11.98 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 26,562 | Target Price | 22.13 |
Oper. Margin | - | Earnings Date | - | Volume | 6,367 | Change | -3.85% |
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.
Ladenburg Thalmann | Neutral | Apr 29, 24 |
BMO Capital | Outperform | Apr 26, 24 |
JMP Securities | Market Outperform | Apr 25, 24 |
Piper Sandler | Overweight | Apr 25, 24 |
HC Wainwright & Co. | Buy | Apr 25, 24 |
Ladenburg Thalmann | Buy | Apr 5, 24 |
BMO Capital | Outperform | Apr 1, 24 |
JMP Securities | Market Outperform | Apr 1, 24 |
HC Wainwright & Co. | Buy | Mar 28, 24 |